Please Wait
Applying Filters...
menu
    • menu
    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    DATA COMPILATION
    #PharmaFlow

    Pipeline Prospector March 2026 highlights: Lilly to acquire Centessa for US$ 7.8 bn; Merck buys Terns Pharma for US$ 6.7 bn

    Stock Recap
    #PipelineProspector

    Menu

    Risperidone (RIS)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Supplier Contact Email Supplier's Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    Interquim SA mheras@ferrer.com https://www.pharmacompass.com/pharma-services/api-manufacturing-services/interquim-sa
    Spain
    		 INTERQUIM SA 18257 RISPERIDONE 2005-04-11 Active II Complete 2021-03-02 2020-09-29
    Inke S.A contact-inke@inke.es https://www.pharmacompass.com/pharma-services/api-manufacturing-services/inke-sa
    Spain
    		 INKE SA 15682 RISPERIDONE 2001-10-23 Active II Complete 2021-06-09 2021-06-04
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.